GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Net Interest Income (for Banks)

Adynxx (FRA:HL1C) Net Interest Income (for Banks)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Adynxx (FRA:HL1C) Business Description

Industry
Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.